Almirall in figures

Our figures are the result of combining an outstanding business structure, an excellent team of professionals, sound values, an international perspective and substantial investment in R&D, all resulting in a high quality product portfolio which allows us to offer the best therapeutic solutions for people all over the world.

Net sales

General data 2009

Net sales (*)

(in millions of euros)

Spanish market: 536
Foreign market: 389,5
Total: 925,5

(*) Local sales, Almirall and partners.

Market share in Spain: 5,4

Percentage of proprietary products over total income: aprox 45%

Own R&D products

(geographical location)

Aceclofenac: Europe, Asia-Pacific, Africa, Middle East, Central America and South America.
Almagate: Europe, Asia-Pacific and Central America.
Almotriptan: Europe and North America.
Cinitrapide: Europe and Central America.
Clebopride: Europe and Asia-Pacific.
Ebastine: Europe,Africa, Asia-Pacific, Middle East, Central America and South America.
Piketoprofen: Europe.

Resources in R&D

Around 15% over net sales
Around 15% of the workforce

Ten best-selling products

63% of sales in 2009 corresponded to the company's ten best-selling products, with three of them being Almirall R&D products:

	Active Ingredient	Therapeutic Area	Pathology
1	Ebastine *	Respiratory	Allergy
2	Atorvastatin	Cardiovascular	Cholesterol
3	Escitalopram	Central nervous system	Depression
4	Salmeterol + fluticasone	Respiratory	Asthma COPD
5	Almotriptan *	Central nervous system	Migraine
6	Candesartan cilexetil	Cardiovascular	Hypertension
7	Aceclofenac *	Osteomuscular	Pain
8	Lansoprazol	Digestive	Ulcers
9	Venlafaxine	Central nervous system	Depression
10	Diclofenac sodium + hialuronic acid	Dermatology	Actinic keratoses

(*) Almirall R&D products

Workforce 2010 (estimated)

(includes full time equivalence)

Spain: 1.800
International: 1.300
Total: 3.100
Global R&D: 550
R&D Sant Feliu: Almost 350

Work centres

Headquarters

Barcelona

R&D

3 R&D centres: Sant Feliu (Barcelona - Spain), Bad Homburg (Frankfurt - Germany) and Reinbek (Germany).
2 Units: Chemical Synthesis in Sant Just Desvern and Active Ingredient Scale-up Unit in Sant Andreu de la Barca (Barcelona - Spain).

Production

5 centres:

3 pharmaceutical plants in Sant Andreu de la Barca, Sant Just Desvern (Barcelona - Spain) and Reinbek (Germany).
2 chemical plants in Sant Andreu de la Barca and Sant Celoni (Barcelona - Spain).